Lupus & antiphospholipid syndrome

Impact of belimumab therapy on the quality of life in patients with systemic lupus erythematosus: A cohort study

LupusPublished Prospective cohort study

Authors' conclusion

Before belimumab therapy, SLE patients had a worse HRQoL than the control group, based on both questionnaires, but after belimumab treatment the outcome scores between SLE patients and controls were similar, suggesting that belimumab therapy resulted in a strong improvement in HRQoL.

Study context

Population
Patients with systemic lupus erythematosus (SLE) treated with belimumab, Italy (Italian SLEQoL)
Participants
46 vs 40
Exposure
SLE patients before vs after 6 months of belimumab; SLE patients vs age-matched healthy controls
  • SLEn = 46
  • Healthy controlsn = 40reference
Outcome
HRQoL by SF-36 and SLEQoL
Follow-up
6 months
Methodological detailsbefore–after comparison, age-matched healthy controls
  • Before–after comparison
  • Age-matched healthy controls

Main finding

As reported in the abstract

HRQoL (SF-36, SLEQoL) before vs after belimumab
  • Belimumab significantly improved health-related QoL (HRQoL) according to SF-36 and SLEQoL
  • Decrease in all six SLEQoL domains and increase in all eight SF-36 domains
  • Before belimumab, SLE patients had worse HRQoL than controls; after treatment scores were similar

Observational data: associations, not effects.

Further findings

Median prednisone dose after belimumab · 6 months

Belimumab treatment led to a reduction in the median prednisone dose, to 0 mg/day (IQR 0-4.5 mg/day)

SELENA-SLEDAI score (disease activity) · 6 months

Decrease in SELENA-SLEDAI score after belimumab

HRQoL, SLE patients vs healthy controls

Before belimumab, SLE patients had worse HRQoL than controls on both questionnaires; after belimumab, scores were similar

Original publication

Impact of belimumab therapy on the quality of life in patients with systemic lupus erythematosus: A cohort study. Lupus. Published 30 October 2023. doi:10.1177/09612033231210607

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.